company background image
6589 logo

EirGenix TPEX:6589 Stock Report

Last Price

NT$94.30

Market Cap

NT$28.9b

7D

2.1%

1Y

-13.9%

Updated

17 Jul, 2024

Data

Company Financials +

6589 Stock Overview

Operates as a contract development and manufacturing company in Taiwan and internationally.

6589 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

EirGenix Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for EirGenix
Historical stock prices
Current Share PriceNT$94.30
52 Week HighNT$112.00
52 Week LowNT$76.50
Beta0.64
11 Month Change10.94%
3 Month Change17.00%
1 Year Change-13.88%
33 Year Change-30.15%
5 Year Change178.17%
Change since IPO109.60%

Recent News & Updates

Recent updates

Market Sentiment Around Loss-Making EirGenix Inc. (GTSM:6589)

Apr 08
Market Sentiment Around Loss-Making EirGenix Inc. (GTSM:6589)

Is EirGenix (GTSM:6589) Using Debt Sensibly?

Mar 03
Is EirGenix (GTSM:6589) Using Debt Sensibly?

Should EirGenix (GTSM:6589) Be Disappointed With Their 73% Profit?

Jan 07
Should EirGenix (GTSM:6589) Be Disappointed With Their 73% Profit?

Shareholder Returns

6589TW Life SciencesTW Market
7D2.1%-0.4%0.4%
1Y-13.9%-12.5%37.6%

Return vs Industry: 6589 underperformed the TW Life Sciences industry which returned -12.5% over the past year.

Return vs Market: 6589 underperformed the TW Market which returned 37.6% over the past year.

Price Volatility

Is 6589's price volatile compared to industry and market?
6589 volatility
6589 Average Weekly Movement5.0%
Life Sciences Industry Average Movement5.0%
Market Average Movement4.7%
10% most volatile stocks in TW Market8.5%
10% least volatile stocks in TW Market2.2%

Stable Share Price: 6589 has not had significant price volatility in the past 3 months.

Volatility Over Time: 6589's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012n/aLee-Cheng Liuwww.eirgenix.com

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage.

EirGenix Inc. Fundamentals Summary

How do EirGenix's earnings and revenue compare to its market cap?
6589 fundamental statistics
Market capNT$28.87b
Earnings (TTM)-NT$815.74m
Revenue (TTM)NT$1.03b

28.1x

P/S Ratio

-35.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6589 income statement (TTM)
RevenueNT$1.03b
Cost of RevenueNT$810.18m
Gross ProfitNT$215.84m
Other ExpensesNT$1.03b
Earnings-NT$815.74m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.66
Gross Margin21.04%
Net Profit Margin-79.50%
Debt/Equity Ratio5.0%

How did 6589 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.